Drugs & Targets FDA approves Gomekli for pediatric patients with neurofiromatosis type 1 February 14, 2025Vol.51 No.06
Drugs & Targets EC grants marketing authorization for Removab as a treatment for malignant ascites February 14, 2025Vol.51 No.06
Drugs & Targets Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology February 14, 2025Vol.51 No.06
White House Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutionsThe move could gut academic cancer research February 10, 2025Vol.51 No.06By Paul Goldberg
White House “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and genderMedical group sues over removing “information used every day by health professions” February 07, 2025Vol.51 No.05By Jacquelyn Cobb and Katie Goldberg
Capitol Hill Senate Finance Committee advances RFK Jr. to likely confirmation, with Bill Cassidy (R-LA) casting the deciding vote February 07, 2025Vol.51 No.05By Claire Marie Porter
Guest Editorial Communication—We need more, not less February 07, 2025Vol.51 No.05By W. Kimryn Rathmell
Guest Editorial World Cancer Day 2025: A symbol of personal and collective uncertainty February 07, 2025Vol.51 No.05By Ruth Fein Revell
Trials & Tribulations LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment February 07, 2025Vol.51 No.05By Lee Greenberger
Trials & Tribulations Physicians and biopharma should improve accessibility of cancer trials February 07, 2025Vol.51 No.05By Michel van Harten
